Nigara Yerkhojayeva

Dr. Nigara Yerkhojayeva

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 2024 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
RKRauan Kaiyrzhanov
Rauan Kaiyrzhanov
NZNazira нет Zharkinbekova
Nazira нет Zharkinbekova
UGUlviyya Guliyeva
Ulviyya Guliyeva
MGManizha Ganieva
Manizha Ganieva
ZTZaruhi Tavadyan
Zaruhi Tavadyan
HHHenry Houlden
Henry Houlden

27 April 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
NMNurlybek Mombekov
Nurlybek Mombekov
NYNigara Yerkhojayeva
Nigara Yerkhojayeva
IDIslamxan Doszhanova
Islamxan Doszhanova
NZNazira нет Zharkinbekova
Nazira нет Zharkinbekova
НNНұрдинов Нұрсұлтан Nuskabayeva
Нұрдинов Нұрсұлтан Nuskabayeva
NNNursultan Nurdinov
Nursultan Nurdinov
Background/Objectives: Epilepsy is a long-term condition that affects the brain and has a big impact on a person’s daily life, especially in areas where people do not have a lot of money or access to good healthcare. This study aimed to evaluate the relationship between medication adherence and QoL and to assess the role of seizure severity in the association between them among patients with epilepsy. Methods: A cross-sectional study of 1100 adult patients with epilepsy was conducted using registry data and structured interviews. The main outcomes that were assessed are quality of life (QoL), medication adherence, and seizure severity. Results: Reduced QoL was observed in 62% of patients. Low medication adherence was significantly associated with reduced QoL (OR = 4.33 [3.24–5.79] unadjusted; 3.90 [3.07–5.80] fully adjusted). Seizure severity was also associated with reduced QoL (OR = 1.62, p = 0.002; OR = 2.05, p < 0.001). Cognitive impairment showed the strongest association with reduced QoL, with ORs of 14.6 for mild and 80.8 for moderate-severe impairment in unadjusted models, remaining significant after adjustment. Medication adherence was significantly associated with seizure severity (OR = 1.18, p = 0.002), and attenuation of its effect after adjustment suggests that these variables are interrelated, although causality cannot be determined in this study. Additional factors associated with reduced QoL included lower education, longer disease duration, polytherapy, structural brain abnormalities, and comorbidities. Conclusions: Reduced QoL in epilepsy is strongly influenced by cognitive impairment and medication nonadherence, with seizure severity potentially contributing to this association, although causality cannot be inferred. These findings support integrated care strategies targeting adherence, cognition, and seizure control to improve patient outcomes.

Verified
Journal Article
Open access
PDF file
NYNigara Yerkhojayeva
Nigara Yerkhojayeva
NZNazira нет Zharkinbekova
Nazira нет Zharkinbekova
SASovet Azhayev
Sovet Azhayev
AOAinash Oshibayeva
Ainash Oshibayeva
НNНұрдинов Нұрсұлтан Nuskabayeva
Нұрдинов Нұрсұлтан Nuskabayeva
RKRauan Kaiyrzhanov
Rauan Kaiyrzhanov
Background: Rare pediatric neurological diseases (RPND) often remain undiagnosed for years, creating prolonged and costly diagnostic odysseys. Combining Human Phenotype Ontology (HPO)-based deep phenotyping with exome sequencing (ES) and reverse phenotyping offers the potential to improve diagnostic yield, accelerate diagnosis, and support sustainable healthcare in resource-limited settings. Objectives: To evaluate the diagnostic yield and clinical impact of an integrated approach combining deep phenotyping, ES, and reverse phenotyping in children with suspected RPNDs. Methods: In this multicenter observational study, eighty-one children from eleven hospitals in South Kazakhstan were recruited via the Central Asian and Transcaucasian Rare Pediatric Neurological Diseases Consortium. All patients underwent standardized HPO-based phenotyping and ES, with variant interpretation following ACMG guidelines. Reverse phenotyping and interdisciplinary discussions were used to refine clinical interpretation. Results: A molecular diagnosis was established in 34 of 81 patients (42%) based on pathogenic or likely pathogenic variants. Variants of uncertain significance (VUS) were identified in an additional 9 patients (11%), but were reported separately and not included in the diagnostic yield. Reverse phenotyping clarified or expanded clinical features in one-third of genetically diagnosed cases and provided supportive evidence in most VUS cases, although their classification remained unchanged. Conclusions: Integrating deep phenotyping, ES, and reverse phenotyping substantially improved diagnostic outcomes and shortened the diagnostic odyssey. This model reduces unnecessary procedures, minimizes delays, and provides a scalable framework for advancing equitable access to genomic diagnostics in resource-constrained healthcare systems.

30 June 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
NYNigara Yerkhojayeva
Nigara Yerkhojayeva
NZNazira нет Zharkinbekova
Nazira нет Zharkinbekova
SASovet Azhayev
Sovet Azhayev
AOAinash Oshibayeva
Ainash Oshibayeva
НNНұрдинов Нұрсұлтан Nuskabayeva
Нұрдинов Нұрсұлтан Nuskabayeva
RKRauan Kaiyrzhanov
Rauan Kaiyrzhanov
Background: Rare pediatric neurological diseases (RPND) often elude timely diagnosis, resulting in prolonged and costly diagnostic odysseys. Integration of Human Phenotype Ontology (HPO)-based deep phenotyping with exome sequencing (ES) and reverse phe-notyping may improve diagnostic yield and efficiency, especially in resource-limited set-tings. Objectives: To assess the diagnostic yield and clinical impact of an integrated ap-proach combining deep phenotyping, ES, and reverse phenotyping in children with sus-pected RPND in a multi-center, resource-limited setting. Methods: Eighty-one children with suspected RPND from 11 hospitals in South Kazakhstan were enrolled via the Cen-tral Asian and Transcaucasian Rare Pediatric Neurological Diseases Genomic Consorti-um (CAT-RPND). ES was performed by 3Billion (South Korea). All patients underwent HPO-based deep phenotyping, with variant classification according to American College of Medical Genetics and Genomics (ACMG) guidelines. Reverse phenotyping and inter-disciplinary case discussions supported interpretation. Results: Molecular diagnoses were achieved in 43 of 81 patients (53%), including 18 pathogenic, 12 likely pathogenic, and 9 variants of uncertain significance (VUS). Reverse phenotyping refined or expanded phenotypes in 33% of diagnosed cases and supported likely pathogenicity in 8 of 9 VUS. The integrated approach reduced the median diagnostic odyssey from 72 to < 5 months and the median number of procedures from 20 to 2 (Wilcoxon p = 1.91×10⁻⁶; Cohen’s d = 2.43). Conclusions: Combining deep phenotyping, ES, and reverse phenotyping improved diagnostic outcomes and shortened the diagnostic journey. This approach minimizes unnecessary procedures and delays, offering scalable value for sustainable healthcare in resource-limited settings.

7 September 2025 in Journal of Clinical Medicine of Kazakhstan
Verified
Journal Article
Open access
NYNigara Yerkhojayeva
Nigara Yerkhojayeva
NZNazira нет Zharkinbekova
Nazira нет Zharkinbekova
SASovet Azhayev
Sovet Azhayev
AOAinash Oshibayeva
Ainash Oshibayeva
НNНұрдинов Нұрсұлтан Nuskabayeva
Нұрдинов Нұрсұлтан Nuskabayeva
RKRauan Kaiyrzhanov
Rauan Kaiyrzhanov
Introduction: Complex neurological phenotypes (CNPs) in pediatric patients often involve multiple coexisting syndromes that challenge conventional diagnostic pathways. In the present study, we evaluated the diagnostic algorithm developed by our team—“Deep Phenotyping–Based Diagnostic Algorithm for Complex Neurological Phenotypes”—which integrates deep phenotyping and genomics. Methods: In this single-center retrospective study, 28 children (0–18 years) with CNPs were assessed at the Diagnostic Center Clinic of Khoja Akhmet Yassawi International Kazakh-Turkish University between January and December 2023. Clinical features were encoded as standardized Human Phenotype Ontology (HPO) terms, which were entered into the Phenomizer platform to generate ranked candidate genes. Proband whole exome sequencing (WES) was performed for all participants. Reverse phenotyping re-examined clinical data in light of genetic findings. The algorithm’s diagnostic yield and concordance between prioritization and confirmed diagnoses were analyzed descriptively. Results: A molecular diagnosis was established in 14 of 28 patients (50%). Confirmed etiologies included monogenic neurodevelopmental syndromes, metabolic disorders, mitochondrial encephalopathy, craniosynostosis, and chromosomal aberrations. In all single-gene cases, the causal gene ranked within Phenomizer’s top five candidates. Reverse phenotyping corroborated genotype–phenotype correlations and revealed additional clinical features in select patients. Conclusions: This multi-step algorithm achieved a 50 % diagnostic yield—exceeding typical WES-only approaches—and demonstrated robust concordance between phenotype-driven prioritization and molecular results. The framework is feasible in resource-limited settings and may streamline the genetic workup of complex pediatric neurological disorders.

Verified
Journal Article
Open access
PDF file
NMNurlybek Mombekov
Nurlybek Mombekov
NYNigara Yerkhojayeva
Nigara Yerkhojayeva
AUAliya Ualiyeva
Aliya Ualiyeva
NZNazira нет Zharkinbekova
Nazira нет Zharkinbekova
ÇÖÇiğdem Özkara
Çiğdem Özkara
NNNursultan Nurdinov
Nursultan Nurdinov
Background/Objectives: Adult epilepsy is clinically heterogeneous, and individual clinical predictors may not fully capture the multidimensional burden associated with drug-resistant epilepsy (DRE). This study aimed to identify latent clinical phenotypes in adults with epilepsy and examine their cross-sectional associations with DRE and broader disease burden. Methods: This regional observational cohort study used a source database of 1100 patients with epilepsy. After excluding two patients aged <18 years, the adult analytic cohort included 1098 patients. Complete-case latent class analysis (LCA) was performed in 1054 patients using age at onset, disease duration, seizure type, seizure frequency, serial seizures/status, postictal confusion, neurological status, neuroimaging category, and number of antiseizure medications. Model selection was based on statistical fit, class size, and clinical interpretability. Internal clinical validation outcomes included DRE, quality of life, cognitive screening, and stigma scores. Post hoc characterization described the classes by epilepsy etiology, derived epilepsy type, and seizure categories aligned with current terminology. Results: A three-class solution was selected, with class sizes of 314, 465, and 275. DRE prevalence increased stepwise across classes: 5.7%, 14.2%, and 33.1%, respectively (p < 0.001). In adjusted analysis, Class 2 had higher odds of DRE than Class 1 (odds ratio 2.70, 95% confidence interval 1.56–4.67), while Class 3 showed the strongest association (odds ratio 8.19, 95% confidence interval 4.15–16.16; both p < 0.001). Higher-burden classes showed lower quality-of-life and cognitive scores and higher stigma scores. Conclusions: LCA identified three clinically interpretable, burden-enriched phenotypic profiles associated with a stepwise gradient in DRE and broader multidimensional disease burden. These cross-sectional profiles may provide a useful framework for describing clinical heterogeneity in adult epilepsy and generating hypotheses for future validation studies.